We believe this site might serve you best::

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

cAMP-Glo™ Max Assay

Faster cAMP Detection for High-Throughput Assays

  • Complete in ~30 minutes
  • Scalable to 1536-well plate formats and beyond
  • No interference by fluorescent compounds

Size

Catalog number selected: V1681

$ 360.00 Your price: Log In

cAMP-Glo™ Max Assay
2 plates
$ 360.00
Your price: Log In
Change Configuration

Bioluminescent Detection of cAMP to Monitor GPCR Activity

The cAMP-Glo™ Max Assay is a homogeneous, bioluminescent, high-throughput assay to measure cyclic AMP (cAMP) levels in cells. Compounds that modulate GPCRs coupled with adenylate cyclase typically alter intracellular cAMP levels. The assay monitors cAMP levels in cells in response to the effect of agonists, antagonists or test compounds on G protein-coupled receptors (GPCRs), and is based on the principle that cyclic AMP (cAMP) stimulates protein kinase A (PKA) holoenzyme activity, decreasing available ATP and leading to decreased light production in a coupled luciferase reaction.

Improved Format for Better Performance

This improved version of the cAMP-Glo™ Assay combines the lysis and cAMP reaction buffers into the cAMP-Glo™ ONE Buffer, streamlining the protocol and speeding up the assay. The ONE Buffer is supplied at 5X concentration, which provides increased flexibility for starting cell culture volumes.

The cAMP-Glo™ Max Assay allows easy quantitation of cAMP levels in broad range of cell types, and can be performed in 96-, 384- or 1536-well plates. Cells are induced with a test compound for an appropriate period of time to modulate cAMP levels. After induction, cells are lysed and the cAMP released stimulates protein kinase A in the reagent. The Kinase-Glo® Reagent is then added to terminate the PKA reaction and detect the remaining ATP via a luciferase reaction. Plates are read using a microplate-reading luminometer. The half-life for the luminescent signal is greater than 4 hours, providing ample time to read plates and eliminating the need for luminometers with reagent injectors.

Cat.# V1681 contains sufficient reagents for 2 plates (96- or 384-well format).
Cat.# V1682 contains sufficient reagents for 20 plates (96- or 384-well format).
Cat.# V1683 contains sufficient reagents for 200 plates (96- or 384-well format).

6127MA.eps
Schematic diagram of cAMP production in cells and the cAMP-Glo™ Max Assay.

Fast and Easy to Use

  • Improved—Lysis and cAMP detection steps combined (cAMP-Glo™ ONE Buffer).
  • ONE Buffer—5X concentration provides better flexibility for starting cell culture volumes.
  • Assay complete in approximately 30 minutes.

Excellent Signal:Noise Ratios

  • Best signal:background ratio of all the cAMP assays.
  • Signal:Background >200 (with cAMP), >15 (on cells).

Proven Luminescence Technology

  • Powered by Ultra-Glo™ Recombinant Luciferase.
  • No interference by fluorescent compounds.
  • Non-radioactive.

Protocols

Specifications

You are viewing: 2 plates Change Configuration

What's in the box?

Item Part # Size

Protein Kinase A

V135A 1 x 20μl

cAMP-Glo™ ONE Buffer

V166A 1 x 2.5ml

MgCl2, 1M

V330A 1 x 1ml

cAMP, 1mM

V642B 1 x 100μl

Kinase-Glo® Substrate

V672A 1 x 1 vial

Kinase-Glo® Buffer

V673A 1 x 10ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. No. 7,700,310 and other patents and patents pending.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

Patent Pending.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

Specifications

You are viewing: 20 plates Change Configuration

What's in the box?

Item Part # SizeConcentration

Protein Kinase A

V135B 1 x 200μl

cAMP-Glo™ ONE Buffer

V166B 1 x 20ml

MgCl2

V330B 1 x 5ml1M

cAMP, 1mM

V642A 1 x 500μl

Kinase-Glo® Substrate

V672B 1 x 1 vial

Kinase-Glo® Buffer

V673B 1 x 100ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. No. 7,700,310 and other patents and patents pending.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

Patent Pending.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

Specifications

You are viewing: 10 × 20 plates Change Configuration

What's in the box?

Item Part # SizeConcentration

Protein Kinase A

V135B 10 x 200μl

cAMP-Glo™ ONE Buffer

V166B 10 x 20ml

MgCl2

V330B 4 x 5ml1M

cAMP, 1mM

V642A 6 x 500μl

Kinase-Glo® Substrate

V672B 10 x 1 vial

Kinase-Glo® Buffer

V673B 10 x 100ml

SDS

Choose language:

Certificate of Analysis

Search for Specific Certificate:

View more results
No results
Loading…

Use Restrictions

For Research Use Only. Not for Use in Diagnostic Procedures.

Storage Conditions

BB

 

Patents and Disclaimers

U.S. Pat. Nos. 7,083,911, 7,452,663 and 7,732,128 and other patents.

U.S. Pat. No. 7,700,310 and other patents and patents pending.

U.S. Pat. Nos. 7,741,067, 8,361,739 and 8,603,767 and other patents and patents pending.

Patent Pending.

U.S. Pat. Nos. 6,602,677, 7,241,584, 8,030,017 and 8,822,170 and other patents and patents pending.

Resources

Choose your country

Americas

Brazil
Brazil
Canada
Canada
United States
United States

Pacific Asia

Australia
Australia
India
India
Japan
Japan
Korea, Republic of
Korea, Republic of
Singapore
Singapore

Europe

Austria
Austria
Belgium
Belgium
Denmark
Denmark
Estonia
Estonia
Finland
Finland
France
France
Germany
Germany
Iceland
Iceland
Italy
Italy
Luxembourg
Luxembourg
Netherlands
Netherlands
Norway
Norway
Poland
Poland
Spain
Spain
Sweden
Sweden
Switzerland
Switzerland
United Kingdom
United Kingdom